NOVO NORDISK A S (NVO) Form 6-K — Sep 17, 2026
Novo Nordisk announced that the EMA's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending EU marketing authorisation for FREHEMGO (denecimig), a next-generation factor VIIIa mimetic for haemophilia A with or without inhibitors, in adults and children. FREHEMGO would be the first FVIIIa mimetic to offer once-monthly, once-every-two-weeks and once-weekly prophylaxis in a single-use pre-filled pen. The recommendation rests on the FRONTIER trial programme, which showed consistently low mean annualised bleeding rates, generally below 1 in the phase 3 population, and no new safety signals when switching directly from emicizumab.
Key figures
- Employees
- 67000
- Expected Eu Launch
- Q4 2026 in first European countries; broadly across the EU starting early 2027
- Fda Bla Submission
- September 2025 (still pending)
- Announcement Number
- 55 / 2026
- Years In Haemophilia
- over 40 years
- Mean Annualised Bleeding Rate
- generally below 1 in the reported phase 3 population across the FRONTIER programme
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.